Inova is Northern Virginia’s leading nonprofit healthcare provider with more than 2 million patient visits each year through an integrated network of hospitals, primary and specialty care practices, emergency and urgent care centers, outpatient services, and destination institutes. Screening of controlled substance waste with WasteLog™ will be introduced at Inova Fair Oaks Hospital, a 174-bed acute care community hospital serving the rapidly growing suburbs of Northern Virginia.

Lars Gusch, CEO of Pharmacolog comments: “I’m excited that Pharmacolog’s journey with WasteLog™ enhancing the Drug Diversion Prevention Programs of our customers continues with this latest order from our new customer in Virginia.”

About Pharmacolog

Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.

The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, DrugLog™, WasteLog™, PrepLog™ and Pharmacolog Dashboard™.

Further information regarding the company is available at https://pharmacolog.com/.

The company's Certified Adviser is Mangold Fondkommission AB.

NEW YORK, NY - Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 4 million shares of Pfizer common stock at a price of $27.35 per share in cash. TRC Capital Investment’s offer price of $27.35 per share is approximately 4.4 percent lower than the $28.61 closing share price of Pfizer’s common stock on December 27, 2023 – the business day prior to the date of the offer. The offer is for approximately 0.071 percent of the shares of Pfizer common stock outstanding as of the December 28, 2023 offer date.

Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in response to TRC Capital Investment’s offer because the offer is at a price below the current market price for Pfizer’s shares and subject to numerous conditions. Pfizer is not affiliated or associated in any way with TRC Capital Investment, its mini-tender offer or its offer documentation.

TRC Capital Investment’s has made many similar mini-tender offers for shares of other companies. Mini-tender offers seek to acquire less than 5 percent of a company’s shares outstanding, thereby avoiding many disclosure and procedural requirements of the U.S. Securities and Exchange Commission (SEC) that apply to offers for more than 5 percent of a company’s shares outstanding. As a result, mini-tender offers do not provide investors with the same level of protections as provided for larger tender offers under U.S. securities laws.

The SEC has cautioned investors that some bidders making mini-tender offers at below-market prices are “hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” More on the SEC’s guidance to investors on mini-tender offers is available at www.sec.gov/investor/pubs/minitend.htm.

Pfizer urges investors to obtain current market quotations for their shares, to consult with their broker or financial advisor and to exercise caution with respect to TRC Capital Investment’s offer. Pfizer recommends that stockholders who have not responded to TRC Capital Investment’s offer take no action. Stockholders who have already tendered their shares may withdraw them at any time prior to the expiration of the offer, in accordance with TRC Capital Investment’s offer documentation. The offer is currently scheduled to expire at 12:01 a.m., New York City time, on January 30, 2024. TRC Capital Investment may extend the offering period at its discretion.

Pfizer encourages brokers and dealers, as well as other market participants, to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosure at www.sec.gov/divisions/marketreg/minitenders/sia072401.htm.

Pfizer requests that a copy of this news release be included with all distributions of materials relating to TRC Capital Investment’s mini-tender offer related to shares of Pfizer common stock.

Cleveland Clinic has appointed Lindsey B. Amerine, Pharm.D., MS, BCPS, CPEL, FASHP, as Chief Pharmacy Officer. She will begin on February 26 and will oversee enterprise pharmacy initiatives. 

Dr. Amerine joins Cleveland Clinic from UNC Health, where she most recently served as Interim Chief Pharmacy Officer and Vice President of Pharmacy from May to September last year and System Executive Director of Pharmacy since February 2022 overseeing clinical, operational, and financial services. 

Dr. Amerine will lead more than 1,500 full-time pharmacy professionals in Ohio and Florida, and will report to Donald A. Malone Jr., M.D., Cleveland Clinic Executive Vice President and President of the Northeast Ohio Market. 

“Dr. Amerine is a thoughtful and innovative healthcare leader with vast experience in pharmacy operations,” said Dr. Malone. “Under her leadership, Cleveland Clinic will continue its world-leading pharmacy practices and enhance our services with automation and technology.” 

Dr. Amerine has held other leadership roles at UNC Health, including coordinator for the Health-System Pharmacy Administration and Leadership residency program, and was associate professor of clinical education at the University of North Carolina Eshelman School of Pharmacy. 

“Cleveland Clinic’s pharmacy operations are highly regarded,” said Dr. Amerine. “I’m excited to join the team and continue to look for new ways to serve patients and innovate in this ever-changing pharmacy environment.” 

Throughout her career, Dr. Amerine has been active with the American Society of Health-System Pharmacists (ASHP), where she serves as the immediate past chair of ASHP’s section of pharmacy practice leaders and was selected as a fellow of ASHP in 2020. She has over 50 peer-reviewed publications and presents on pharmacy practice topics nationally and internationally. 

She received the 2012, 2013, 2015 and 2022 ASHP Best Practice Awards, 2015 ASHP Foundation Literature Award, 2017 ASHP Foundation Excellence in Medication Safety Award, and 2018 and 2019 Association of Community Cancer Centers (ACCC) Innovator Awards.  

A Nebraska native, Dr. Amerine received her Doctor of Pharmacy degree from the University of Wyoming School of Pharmacy and her Master of Science degree, with a focus on health-system pharmacy administration, from the University of North Carolina Eshelman School of Pharmacy. 

Allison Riffle, Pharm.D., MS, has served as Cleveland Clinic’s interim Chief Pharmacy Officer since April 2023. 

PARIS, FRANCE - Brian Foard, a healthcare industry veteran and Sanofi leader in the U.S., has been named Head of the company’s Specialty Care Global Business Unit (GBU). With this appointment, which is effective immediately, Brian becomes a member of Sanofi’s Executive Committee. 

Brian has been interim Head of the GBU since September 2023 while also serving as Head of Specialty Care North America and U.S. Country Lead. Brian, who has more than 20 years of specialty biopharma experience, has been at the helm of the successful launch of Dupixent® in more than 50 countries across multiple indications and age groups prior to his current role. 

Paul Hudson, Chief Executive Officer, Sanofi 

“I am very excited to have Brian join our Executive Committee. He is clearly one of our leaders who has been actively contributing to the success of our Play to Win strategy while embracing our culture and values. His ability to motivate teams and inspire success across the globe is underpinned by his determination, strategic mindset and dedication to continue to transform Sanofi into a world leading immunology company. Brian’s best-in-class launch of Dupixent will help to set our roadmap for the first- and best-in-class molecules we are preparing to launch in the coming years.” 

Brian joined Sanofi in March 2017 as the Global Head of Dermatology and Respiratory, and held roles of increasing responsibility, including as Head of Global Immunology for Sanofi. He began his career with Galderma and spent more than 10 years in the U.S. before relocating to Paris to lead global marketing and launch readiness. During his time at Galderma, Brian also served in roles including General Manager for Australia & New Zealand and Vice President & General Manager of the global prescription business unit. 

Brian received a degree in business from East Carolina University and has completed an executive education course at Wharton. He will be based in Cambridge, Massachusetts. 

Brian Foard, Executive Vice President, Head of Specialty Care, Sanofi 

“I am incredibly excited to take on this global role as Sanofi continues to drive innovation and deliver for patients. Under Paul’s leadership and his Play to Win strategy, Sanofi has set out on a course built for success and Specialty Care is at the core of the company’s ambitions. With this vision, and by doubling down on this work, we will continue to chase the miracles of science to improve people’s lives.”

RAHWAY, NJ & SAN FRANCISCO, CA - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.

“At Merck, we continue to enhance our oncology pipeline through strategic acquisitions that complement our current portfolio and advance breakthrough science to help address the needs of people with cancer worldwide,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “This agreement reflects the creativity and commitment of scientists and clinical development teams at Harpoon. We look forward to further evaluating HPN328 in innovative combinations with other pipeline candidates.”

Harpoon has developed a portfolio of novel T-cell engagers that employ the company’s proprietary Tri-specific T cell Activating Construct (TriTAC^®) platform, an engineered protein technology designed to direct a patient’s own immune cells to kill tumor cells, and ProTriTAC™ platform, applying a prodrug concept to its TriTAC^® platform to create a therapeutic T-cell engager that is designed to remain inactive until it reaches the tumor.

“At Harpoon, we have always been committed to advancing our cancer immunotherapy candidates to improve the lives of patients. With Merck’s recognized leadership in oncology clinical development and global commercial footprint, our lead candidate, HPN328, is well positioned moving forward,” said Julie Eastland, president and chief executive officer, Harpoon Therapeutics. “The talented, passionate and dedicated Harpoon team has made great progress over the past eight years in leveraging our research platform to develop an innovative suite of candidates, and we are pleased that Merck has recognized the significant potential of our pipeline. I want to personally thank all of our key stakeholders, including our entire team at Harpoon, trial participants, physicians and our shareholders, who have supported us.”

Harpoon’s lead candidate, HPN328, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small cell lung cancer (SCLC) and neuroendocrine tumors. HPN328 is currently being evaluated in a Phase 1/2 clinical trial (NCT04471727) evaluating the safety, tolerability and pharmacokinetics of HPN328 monotherapy in patients with advanced cancers associated with expression of DLL3. The study is also evaluating HPN328 in combination with atezolizumab in patients with SCLC. In October 2023, Harpoon announced the presentation of positive interim tolerability and response data for HPN328 in certain patients with SCLC and neuroendocrine tumors.

Additional pipeline candidates include HPN217 targeting B-cell maturation antigen (BCMA), currently in Phase 1 clinical development for the treatment of patients with relapsed/refractory multiple myeloma, and several preclinical stage candidates, including HPN601, a conditionally activated targeting epithelial cell adhesion molecule (EpCAM) for the treatment of certain patients with EpCAM expressing tumors.

Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Harpoon Therapeutics, Inc. for a price per share of $23.00 in cash. The Board of Directors of Harpoon has unanimously approved the transaction. Closing of the acquisition is subject to certain conditions, including approval of the merger by Harpoon’s stockholders, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions. The transaction is expected to close in the first half of 2024 and will be accounted for as an asset acquisition. Merck expects to record a charge (non-tax deductible) of approximately $650 million, or approximately $0.26 per share, that will be included in non-GAAP results in the quarter that the transaction closes.

BRIDGEWATER, NJ - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) today announces that it has launched 39 new retail and injectable medicines in 2023, as compared to 26 new launches in 2022.

In the fourth quarter of 2023, Amneal launched 13 new products, including 5 injectables. New injectable products added include potassium phosphate vials, tranexamic acid and esmolol intravenous bags. These launches provide a strong foundation for higher injectable revenues going forward. In addition, Amneal launched several key new retail products in the fourth quarter, including spironolactone suspension with 180-day exclusivity, valsartan and hydrochlorothiazide tablets, and icosapent capsules.

“We are pleased to have brought an impressive number of new products to market in 2023,” said Dr. Srinivas Kone, Senior Vice President, Generics R&D. “Our R&D portfolio prioritizes complex and high-value products that provide better access to affordable medicines for providers and patients.”

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations, including international expansion; expected or estimated operating results and financial performance; the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our ability to manage our growth through acquisitions and otherwise; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our ability to complete the proposed holding company reorganization on the anticipated timeline or at all and to realize the expected benefits of such reorganization; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our ability to secure satisfactory terms when negotiating a refinancing or other new indebtedness; our dependence on third-party agreements for a portion of our product offerings; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties, including recent events affecting the financial services industry; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our ability to attract, hire and retain highly skilled personnel; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Advance Market Analytics published a new research publication on "Self service Pharmacies Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Self service Pharmacies market was mainly driven by the increasing R&D spending across the world.

Some of the key players profiled in the study are: Medavail (Canada), Aila tech (United States), imageHOLDERS (United Kingdom), Medifriend RX (United States), Bd Rowa (United States), PARTTEAM & OEMKIOSKS (Portugal), Spot RX (United States) and Smart RX Systems (United States).

Get Free Exclusive PDF Sample Copy of This Research at https://www.advancemarketanalytics.com/sample-report/202407-global-self-service-pharmacies-market?utm_source=OpenPR&utm_medium=Suraj

Scope of the Report of Self service Pharmacies:
Self-service pharmacies are facilities within a healthcare setting or standalone locations that allow individuals to access pharmaceutical products and over-the-counter medications without direct assistance from a pharmacist or healthcare professional. These pharmacies are designed to provide convenience and accessibility for customers to obtain medications, health supplies, and sometimes wellness products without requiring direct interaction with pharmacy staff. Customers can browse aisles, select their desired items, and proceed to self-checkout counters or automated systems to complete their purchases. Self-service pharmacies typically offer a range of non-prescription medications, health aids, vitamins, and personal care items, allowing customers to quickly and independently fulfill their immediate healthcare needs. While self-service pharmacies offer convenience, they may also have staff or on-call pharmacists available for consultations or inquiries, ensuring that customers have access to professional advice when needed.

The titled segments and sub-section of the market are illuminated below:
by Type (Patient Facing, Professional Data Feeding), Application (Check-Out, Ordering Repeat Prescriptions, Identity Verification, Stock Control), Features (Digital Forms, Check-In Module, Card Reader, Payment Options, UV-C Disinfection, IR Temperature Sensing, Label Printing), End User (Hospital, Retail Pharmacies, Clinics, Other)

Market Drivers:
Surge in Demand in Efficient and Quick Customer Service at Pharmacies and Hospitals, Rise in Demand in Self-care Diagnostic and Self-care Dispensing and Surge in Demand in Faster Safer and More Accurate Drug Distribution

Market Trends:
Uses of Artificial Intelligence in Self Service Pharmacies

Opportunities:
Continuous Growth in Digitalization, Increasing Growth in Healthcare Infrastructure, Rising Number of Pharmacies over the World and Limited Customization of Kiosk Machines for Self-service Pharmacies

Self-service Pharmacies Market is a valuable source of guidance for individuals and companies.
 

NYC Health + Hospitals today announced that Danielle DiBari, Pharm.D., Senior Vice President of Business Operations, Chief Pharmacy Officer, and Chief Procurement Officer for NYC Health + Hospitals, was recognized by The Journal of Healthcare Contracting in its 2023 ‘Women Leaders in Supply Chain’ list. Dr. DiBari manages the health system’s supply chain, pharmacy services, and business operations. The list recognizes women leaders who are instrumental in navigating the challenges facing supply chain teams as they contribute to the success of their organizations. The leaders are nominated by the readers of The Journal of Healthcare Contracting and selected by the editorial staff, who consider the nominee’s tenure in supply chain, commitment to continued learning, and recent responsibilities and projects. The Journal of Healthcare Contracting is a publication dedicated to the healthcare supply chain, focusing on the interactions of the four primary stakeholders in healthcare contracting: health systems and their facilities, manufacturers and suppliers, distributors, and group purchasing organizations (GPOs).

“Our health system is more resilient, efficient, and unified since Danielle DiBari has taken the helm as Senior Vice President of Business Operations, Chief Pharmacy Officer and Chief Procurement Officer for NYC Health + Hospitals,” said Mitchell Katz, MD, President and Chief Executive Officer of NYC Health + Hospitals. “We are grateful to The Journal of Healthcare Contracting for the recognition of her efforts, as we build a healthier, more equitable city for all.”

In her role, Dr. DiBari oversees supply chain, pharmacy, and business operations, which enable her to identify opportunities for innovation and find cost-effective solutions to any challenge. Through her tenure she overhauled how the health system manages, safeguards, and optimizes its supply chain. These changes have resulted in significant improvements in organizational productivity, positioning the health system for long-term success.

Dr. DiBari and her team are advancing NYC Health + Hospital’s efforts to work as one, unified health system. In 2022, the team received the Premier GPO Supplier Diversity Award for community involvement, diversity business outreach initiatives, and benchmarking and sharing of best practices. This year, the supply chain operation increased its M/WBE utilization from 5% in 2019 to more than 30%. NYC Health + Hospitals was awarded the prestigious GHX Best 50 Award this year, and was inducted into the GHX Millennium Club, joining a group of health care providers who demonstrate outstanding supply chain management to reduce costs and boost efficiency. The health system is again working toward being recognized by GHX in 2024, as it continues to make strides in the provision of high quality, cost-effective care.

“I am deeply honored and grateful to receive this recognition from The Journal of Healthcare Contracting. This acknowledgement is a reflection of the important work that we do to diversify our supply chain with a focus on equity while improving patient outcomes in the communities that we serve,” said Danielle DiBari, Pharm.D., Senior Vice President of Business Operations, Chief Pharmacy Officer, and Chief Procurement Officer for NYC Health + Hospitals.

Prior to joining NYC Health + Hospitals, Dr. DiBari served as SVP of Clinical Operations and Chief of Staff for the Mount Sinai Health System from 2015-2019, where she identified opportunities to drive efficiency throughout the health system. In this position, she was responsible for unifying, coordinating and overseeing the health system’s operational efforts to maximize their impact on the patients and communities they serve. Dr. DiBari joined the Mount Sinai System in 2015 from Northwell Health and prior, CVS/Caremark, where she held positions on the Corporate Management Team. Her varied career includes strategic planning, business unit development, project and product management, marketing and branding, system strategies, training and development program management and delivery, the management of multi-functional work teams, and customer service.

University Hospitals Plymouth NHS Trust is working on the development of a new and improved outpatient pharmacy due to open in Spring 2024.

The new pharmacy will double in size when it moves to a new location adjacent to Derriford hospital’s on-site Costa Coffee shop in the multi-story car park building.  

Chief Pharmacist & Clinical Director of Medicines Optimisation, Kandarp Thakkar, said: “We’re really excited about progress on the new pharmacy which serves thousands of outpatient appointments each week.

“As many who have used the pharmacy recently will know, we have outgrown our current space and this much improved facility will have room for more staff and stock, a better range of services and a much-improved experience for patients."

“We recognize there have been long queues at the pharmacy in recent weeks, so on behalf of UHP and Lloyds Pharmacy, I want to offer our sincere apologies. The level of service and disruption is not something that we expect or want for patients and we’re very sorry to anyone who has been inconvenienced.”

While work is ongoing on the new pharmacy, the Trust has implemented measures such as covered seating.

The new pharmacy will have extended opening times during the weekends to benefit patients who are unable to attend during the week. Demand for UHP outpatient pharmacy services has grown by 25%.

PRINCETON, NJ & SAN DIEGO, CA - Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.

RayzeBio is a clinical-stage radiopharmaceutical therapeutics (“RPT”) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs. Current pipeline programs are targeting the treatment of solid tumors, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), small cell lung cancer, hepatocellular carcinoma and other cancers. There remains a high, unmet need for more effective treatments in solid tumors, and RPTs enable a precision approach to patient treatment. RPTs bind to tumor cells and deliver targeted radiation to induce cancer cell death. Actinium-based RPTs offer potential advantages over currently available RPTs since the high potency and short firing range of the alpha-emitter create the possibility for stronger efficacy and more targeted delivery.

“This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth opportunities in the back half of the decade and beyond,” said Christopher Boerner, Ph.D., Chief Executive Officer of Bristol Myers Squibb. “Radiopharmaceutical therapeutics are already transforming cancer care, and RayzeBio is at the forefront of pioneering the application of this novel modality. We look forward to supporting and accelerating RayzeBio’s preclinical and clinical programs and advancing its highly innovative radiopharmaceutical platform.”

“Acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform will establish Bristol Myers Squibb’s presence in one of the most promising and fastest-growing new modalities for the treatment of patients with solid tumors – delivering radioactive payloads to cancer cells in a targeted manner,” said Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Drug Development of Bristol Myers Squibb. “In addition, RayzeBio’s platform has the potential to be a significant IND engine, generating several therapeutic candidates in the future by leveraging our global drug development capabilities and infrastructure.”

Ken Song, M.D., President and CEO of RayzeBio, said, “Despite therapeutic advances in recent years, the need for more effective treatments in solid tumors persists, and radiopharmaceutical therapeutics are positioned to be an important next wave of innovation in oncology therapy. Bristol Myers Squibb’s well-established presence in oncology and deep expertise in developing, commercializing and manufacturing treatments on a global scale makes it the ideal partner for RayzeBio at this important moment in our evolution. I am excited to see what our team achieves as part of Bristol Myers Squibb.”

RayzeBio’s portfolio includes:

• Lead program RYZ101 (²²⁵Ac-DOTATATE), targeting somatostatin receptor 2 (SSTR2), which is over-expressed in GEP-NETs and extensive stage small cell lung cancer (ES-SCLC). A Phase 3 clinical trial is currently enrolling patients to evaluate RYZ101 in patients with SSTR-positive GEP-NETs who have previously been treated with lutetium-177 based somatostatin therapies. RayzeBio previously reported the interim results of the Phase 1b portion of the ACTION-1 clinical trial, suggesting encouraging efficacy and tolerability. A Phase 1b clinical trial is also currently enrolling patients to evaluate RYZ101 as a first-line treatment of ES-SCLC in combination with standard-of-care therapy.
• RYZ801, RayzeBio’s novel proprietary peptide targeting glypican-3 (GPC3) for delivery of actinium- based radioactivity for the treatment of hepatocellular carcinoma (HCC). RYZ801 is currently in IND-enabling studies.
• Pipeline also includes an asset targeting CA9, which is expressed in renal cell cancer and is currently in IND-enabling studies.
• Multiple first-in-class preclinical assets to treat solid tumors.

RayzeBio is completing construction of a state-of-the-art in-house manufacturing facility in Indianapolis, Indiana, and GMP drug production is expected to begin in the first half of 2024.

The transaction is expected to be treated as a business combination and to be dilutive to Bristol Myers Squibb’s non-GAAP diluted earnings per share by approximately $0.13 in 2024. Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance. Bristol Myers Squibb’s cash flows and strong financial profile enable continued commitment to strong investment-grade credit ratings and investment for growth through business development opportunities and distributions to shareholders through ongoing dividends and share repurchases.

Transaction Terms and Financing

Under the terms of the merger agreement, Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of RayzeBio common stock at a price of $62.50 per share in an all-cash transaction for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. RayzeBio’s Board of Directors unanimously recommends that RayzeBio’s shareholders tender their shares in the tender offer.

The transaction is expected to close in the first half of 2024, subject to customary closing conditions, including the tender of a majority of the outstanding shares of RayzeBio’s common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following the successful closing of the tender offer, Bristol Myers Squibb will acquire all remaining shares of RayzeBio that are not tendered into the tender offer through a second-step merger at the same price of $62.50 per share.